KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection?

Podobne zapisy

• Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?
  od: Veen, Torhild, i wsp.
  Wydane: (2017)
• KRAS Mutation Influences Recurrence Patterns in Patients Undergoing Hepatic Resection of Colorectal Metastases
  od: Kemeny, Nancy E., i wsp.
  Wydane: (2014)
• Addressing the variation in hepatic surgery for colorectal liver metastasis
  od: Guest, Rachel V., i wsp.
  Wydane: (2021)
• Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis
  od: Søreide, Kjetil, i wsp.
  Wydane: (2016)
• KRAS Gene Mutation in Patients Undergoing Liver Resections for Colorectal Cancer. Is There an Advantage to Anatomical Resections?
  od: Silvia Guerrero-S, i wsp.
  Wydane: (2023)